Alector Lands $100 Million Upfront in Genentech Parkinson’s Deal

A $100 million payment means very different things depending on who receives it. For a global drugmaker, it is a line item. For Alector, Inc. (NASDAQ: ALEC), a South San Francisco biotechnology company that closed last Friday with a market value of about $202 million, it equals roughly half of what the whole business was worth. That is the upfront sum Alector will receive from Genentech, a member of the Roche Group whose parent is Roche Holding AG (OTCQX: RHHBY), under a license agreement announced today.

The agreement covers one experimental drug, AL050, which is aimed at Parkinson’s disease. Genentech gets exclusive worldwide rights to develop and sell it, and takes over the development, regulatory, manufacturing and commercial work. Beyond the upfront payment, Alector can earn up to $1.17 billion more if the drug reaches certain development, regulatory and sales goals, plus tiered royalties on any eventual sales. 

To see why a large drugmaker would pay for this, it helps to know two things about the brain. The first is that some people with Parkinson’s have too little of an enzyme called GCase. Without enough of it, certain fatty substances build up inside brain cells and contribute to their decline. The shortage is most pronounced in people who carry mutations in a gene called GBA1, though Alector says it is not limited to them. According to the company, no approved therapy addresses the missing enzyme. 

The second is that the brain is very hard to medicate. A layer of tightly packed cells known as the blood-brain barrier keeps most large molecules in the bloodstream from getting in. That protects the brain, but it also blocks many would-be treatments. Alector’s answer is a technology it calls the Alector Brain Carrier, or ABC, which binds to a receptor on that barrier with the goal of carrying a drug across. AL050 pairs an engineered version of GCase with that carrier.

This is where the deal becomes more than the sale of a single drug. Genentech is licensing AL050, not the carrier. Alector keeps ownership of ABC and the right to use it across the programs it still owns outright. A large partner has, in effect, paid to back one product built on the delivery technology while the technology itself stays with Alector. That is a real vote of confidence, though it is not proof. A license reflects a judgment made on early data, not evidence that the drug works in people. 

The more immediate effect is financial. At the end of June, Alector had $172.8 million in cash and investments, and management expected that to last at least through 2027. The same report showed a company that had been cutting costs, including through staff reductions. With the Genentech payment, chief executive Arnon Rosenthal now says the money should last into 2029. He said it will help take an Alzheimer’s antibody into patient studies and move two other programs toward regulatory filings. 

Investors reacted quickly. Alector’s stock was up 24% in early trading on Monday, the day the agreement was announced. That is a large one-day move for any company, and it shows how much weight the market placed on the news.

Some caution belongs alongside the excitement. AL050 is still in preclinical development, meaning it has been studied in animals and has not yet been given to a person. The $1.17 billion in milestone payments depends on years of trials, regulatory reviews and sales that may never happen. What Alector has for certain is $100 million, a well-known partner for one program, and about two more years of funding to show whether its carrier can do in patients what it has done in the lab.